drugset / Trial / NCT00983255

Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)

NCT00983255

Phase 1 Completed 90 enrolled Merck & Co., Inc.
RandomizedFactorialQuadruple-blindBasic science

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single rising and multiple rising IV doses of TR-701 FA and to determine the absolute bioavailability of oral TR-701 FA following single oral and IV dose administrations in healthy adult subjects.

Timeline

Start
2009-09
Primary completion
2010-01
Completion
2010-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Tedizolid Small molecule 50 mg Intravenous
Subject Tedizolid Small molecule 100 mg Intravenous
Subject Tedizolid Small molecule 200 mg Intravenous
Subject Tedizolid Small molecule 300 mg Intravenous
Subject Tedizolid Small molecule 400 mg Intravenous